Undertreatment of hypercholesterolemia

Current Medical Research and Opinion

Volumn 26, Issue 2, 2010, Pages 439-443

  Daskalopoulou, Stella S ^a   Doonan, Robert J ^a   Mikhailidis, Dimitri P ^b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Adherence; Guidelines; Hypercholesterolemia; Low density lipoprotein cholesterol; Statins; Under treatment

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGE DISTRIBUTION; ARTERY DISEASE; BODY MASS; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; EUROPE; EVIDENCE BASED MEDICINE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; METABOLIC SYNDROME X; NOTE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIMARY PREVENTION; SECONDARY PREVENTION; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PATIENT COMPLIANCE; REFERENCE VALUES; SECONDARY PREVENTION; TREATMENT FAILURE;

EID: 74549217908     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903512396     Document Type: Note

References (48)

1. Daskalopoulou SS. When statin therapy stops: implications for the patient. Curr Opin Cardiol 2009;24:454-460
2. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-467
3. Kamal-Bahl SJ, Burke T, Watson D, et al. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007;99:530-534
4. Hermans MP, Castro Cabezas M, Stranberg T, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin 2010;26:445-454
5. van den Haak P, Heintjes E, Plat A, et al. Determination of non-treatment with statins of high risk patients in the Netherlands. Curr Med Res Opin 2010; 26:271-278
6. De BG, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-1610
7. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
8. Iglseder B, Moroder T, Staffen W, et al. High prevalence and undertreatment of hypercholesterolaemia in participants in a public stroke prevention programme in Austria. Clin Drug Investig 2005;25:709-717
9. Ferrieres J, Bataille V, Leclercq F, et al. Patterns of statin prescription in acute myocardial infarction: the French registry of Acute ST-elevation or non-ST-elevation Myocardial Infarction (FAST-MI). Atherosclerosis 2009;204:491-496
10. Malik S, Lopez V, Chen R, et al. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract 2007;77:126-133
11. Kashani A, Sallam T, Bheemreddy S, et al. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol 2008;101:1606-1613
12. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007;18:401-408
13. Armitage J. The safety of statins in clinical practice. Lancet 2007;370: 1781-1790
14. Tziomalos K, Athyros VG, Karagiannis A, et al. Management of statin-intolerant high-risk patients. Curr Vasc Pharmacol 2010; in press
15. Herrler T, Bohm M, Heeschen C. More good reasons for adherence to statin therapy during acute coronary syndromes. Eur Heart J 2008; 29:2061-2063
16. Tziomalos K, Athyros VG, Mikhailidis DP. Statin discontinuation: an underestimated risk? Curr Med Res Opin 2008;24:3059-3062
17. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocar-dial infarction. JAMA 2007;297:177-186
18. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105:1446-1452
19. Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007;69:904-910
20. Daskalopoulou SS, Delaney JA, Filion KB, et al. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 2008;29:2083-2091
21. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 2008; 117:1028-1036
22. Shalev V, Chodick G, Silber H, et al. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 2009;169:260-268
23. Perreault S, Ellia L, Dragomir A, et al. Effect of statin adherence on cerebro-vascular disease in primary prevention. Am J Med 2009;122:647-655
24. Perreault S, Dragomir A, Blais L, et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol 2009;65:1013-1024
25. Chen H, Ren JY, Xing Y, et al. Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase. Int J Cardiol 2009;131:313-320
26. Lee KT, Lai WT, Chu CS, et al. Effect of withdrawal of statin on C-reactive protein. Cardiology 2004;102:166-170
27. Westphal S, Abletshauser C, Luley C. Fluvastatin treatment and withdrawal: effects on endothelial function. Angiology 2008;59:613-618
28. Bryson CL, Au DH, Sun H, et al. Alcohol screening scores and medication nonadherence. Ann Intern Med 2008;149:795-804
29. Caldwell PH. Review: intensified patient care may improve adherence to lipid-lowering medication in primary or secondary prevention of CV disease. Evid Based Nurs 2008;11:51
30. Choudhry NK, Setoguchi S, Levin R, et al. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiol Drug Saf 2008;17:1189-1196
31. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004;291:1864-1870
32. Gaw A. The care gap: underuse of statin therapy in the elderly. Int J Clin Pract 2004;58:777-785
33. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630
34. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
35. Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol 2008; 51:37-45
36. Kushiro T, Mizuno K, Nakaya N, et al. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension 2009;53:135-141
37. Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and read-mission of patients after myocardial infarction: a six year follow up study. Heart 2002;88:229-233
38. Casebeer L, Huber C, Bennett N, et al. Improving the physician-patient cardiovascular risk dialogue to improve statin adherence. BMC Fam Pract 2009;10:48
39. Jones NE, Dhaliwal R, Day AG, et al. Factors predicting adherence to the Canadian Clinical Practice Guidelines for nutrition support in mechanically ventilated, critically ill adult patients. J Crit Care 2008;23:301-307
40. Patel MR, Chen AY, Roe MT, et al. A comparison of acute coronary syndrome care at academic and nonacademic hospitals. Am J Med 2007; 120:40-46
41. Pletcher MJ, Lazar L, Bibbins-Domingo K, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med 2009;150:243-254
42. Choudhry NK, Patrick AR, Antman EM, et al. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation 2008;117:1261-1268
43. Heart Protection Collaborative Group. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circulation Cardiovascular Quality and Outcomes 2009;2:65-72
44. Tonkin AM, Eckermann S, White H, et al. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study. Am Heart J 2006;151:1305-1312
45. Nherera L, Calvert NW, DeMott K, et al. Cost effectiveness analysis of the use of a high intensity statin compared to a low intensity statin in the management of patients with familial hypercholesterolaemia. Curr Med Res Opin 2010;26: 529-536
46. Liberopoulos EN, Florentin M, Mikhailidis DP, et al. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf 2008;7:717-725
47. Hatzitolios AI, Athyros VG, Karagiannis A et al. IMPROVE Collaborative Group. Implementation of strategy for the management of overt dyslipidemia: The IMPROVE-dyslipidemia study. Int J Cardiol 2009;134: 322-329
48. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyö rä lä K, Keil U. EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009 March 14;373(9667):929-940